CLINICAL TRIAL: STATIN TRIAL

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 动物模型和细胞培养系统的实验室研究、观察性流行病学研究和小型临床试验都有令人信服的证据表明，降低胆固醇可能会减少阿尔茨海默病（AD）的病理学。 这是一项辛伐他汀的临床试验，辛伐他汀是一种HMG CoA还原酶抑制剂，是最常用的一类降脂药，可减少阿尔茨海默病的临床进展。 以下证据支持这一假设，也是本研究的基础。 根据观察性研究和实验室研究的数据，我们假设辛伐他汀将显著降低AD的临床进展（ADAScog测量）。 我们还假设，那些谁使用辛伐他汀将显示有益的影响，安慰剂的措施，日常生活活动，精神和行为症状，生活质量和经济措施。 为了研究这些假设，我们建议招募400名没有高胆固醇血症的AD受试者。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is compelling evidence from laboratory research in animal model and cell culture systems, observational epidemiological studies, and small clinical trials that lowering cholesterol may reduce the pathology of Alzheimer's disease (AD). This is a clinical trial of simvastatin, a HMG CoA reductase inhibitor, the most commonly used class of lipid lowering agents, to reduce the clinical progression of Alzheimer's disease. The following evidence supports this hypothesis and is the basis for this study. Based on data accrued from observational studies, and that derived in the laboratory, we hypothesize that simvastatin will significantly reduce the clinical progression of AD as measured by the ADAScog. We also hypothesize that those who use simvastatin will show beneficial effects over placebo on measures of activities of daily living, psychiatric and behavioral symptoms, quality of life and economic measures. To study these hypotheses, we propose to recruit a cohort of 400 subjects with AD who do not have hypercholesterolemia.